ProPhase Labs, Inc. (PRPH)
USD 0.29
(2.28%)
USD 0.29
(2.28%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.61 Million USD | -191.6% |
| 2022 | 23.59 Million USD | 140.74% |
| 2021 | 9.8 Million USD | 345.95% |
| 2020 | -3.98 Million USD | -23.03% |
| 2019 | -3.23 Million USD | -98.23% |
| 2018 | -1.63 Million USD | 59.05% |
| 2017 | -3.99 Million USD | -50.23% |
| 2016 | -2.65 Million USD | 25.89% |
| 2015 | -3.58 Million USD | 54.22% |
| 2014 | -7.82 Million USD | -1981.73% |
| 2013 | 416 Thousand USD | 137.89% |
| 2012 | -1.09 Million USD | 59.9% |
| 2011 | -2.73 Million USD | 23.82% |
| 2010 | -3.59 Million USD | 8.67% |
| 2009 | -3.93 Million USD | 41.53% |
| 2008 | -6.72 Million USD | -107.96% |
| 2007 | -3.23 Million USD | -35.31% |
| 2006 | -2.39 Million USD | -180.27% |
| 2005 | 2.97 Million USD | 1537.17% |
| 2004 | 181.98 Thousand USD | -71.36% |
| 2003 | 635.53 Thousand USD | 112.03% |
| 2002 | -5.28 Million USD | -1140.48% |
| 2001 | -425.99 Thousand USD | 92.82% |
| 2000 | -5.93 Million USD | 15.21% |
| 1999 | -7 Million USD | -172.16% |
| 1998 | 9.7 Million USD | -72.52% |
| 1997 | 35.3 Million USD | 5142.86% |
| 1996 | -700 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.82 Million USD | 5.68% |
| 2024 Q1 | -8.29 Million USD | 26.9% |
| 2023 Q1 | 875 Thousand USD | 117.19% |
| 2023 Q4 | -11.35 Million USD | -75.24% |
| 2023 FY | -21.61 Million USD | -191.6% |
| 2023 Q3 | -6.47 Million USD | -39.07% |
| 2023 Q2 | -4.65 Million USD | -632.34% |
| 2022 FY | 23.59 Million USD | 140.74% |
| 2022 Q4 | -5.09 Million USD | -360.62% |
| 2022 Q3 | 1.95 Million USD | -81.55% |
| 2022 Q2 | 10.58 Million USD | -34.43% |
| 2022 Q1 | 16.14 Million USD | 18.05% |
| 2021 Q4 | 13.67 Million USD | 475.02% |
| 2021 FY | 9.8 Million USD | 345.95% |
| 2021 Q2 | -1.45 Million USD | -218.76% |
| 2021 Q1 | 1.22 Million USD | 257.96% |
| 2021 Q3 | -3.64 Million USD | -151.52% |
| 2020 Q4 | -773 Thousand USD | -36.33% |
| 2020 Q1 | -812 Thousand USD | -74.25% |
| 2020 Q3 | -567 Thousand USD | -1061.02% |
| 2020 Q2 | 59 Thousand USD | 107.27% |
| 2020 FY | -3.98 Million USD | -23.03% |
| 2019 Q4 | -466 Thousand USD | -1.08% |
| 2019 FY | -3.23 Million USD | -98.23% |
| 2019 Q3 | -461 Thousand USD | 63.64% |
| 2019 Q2 | -1.26 Million USD | -21.46% |
| 2019 Q1 | -1.04 Million USD | -157.14% |
| 2018 Q2 | -260 Thousand USD | -704.65% |
| 2018 FY | -1.63 Million USD | 59.05% |
| 2018 Q1 | 43 Thousand USD | 112.95% |
| 2018 Q3 | -912 Thousand USD | -250.77% |
| 2018 Q4 | -406 Thousand USD | 55.48% |
| 2017 Q3 | -902 Thousand USD | 44.01% |
| 2017 Q2 | -1.61 Million USD | -40.82% |
| 2017 Q4 | -332 Thousand USD | 63.19% |
| 2017 Q1 | -1.14 Million USD | -120.85% |
| 2017 FY | -3.99 Million USD | -50.23% |
| 2016 Q3 | 220 Thousand USD | 120.48% |
| 2016 Q2 | -1.07 Million USD | 16.36% |
| 2016 Q4 | -518 Thousand USD | -335.45% |
| 2016 Q1 | -1.28 Million USD | -3.3% |
| 2016 FY | -2.65 Million USD | 25.89% |
| 2015 Q4 | -1.24 Million USD | -306.14% |
| 2015 Q3 | 603 Thousand USD | 138.51% |
| 2015 Q1 | -1.37 Million USD | -104.6% |
| 2015 FY | -3.58 Million USD | 54.22% |
| 2015 Q2 | -1.56 Million USD | -13.56% |
| 2014 FY | -7.82 Million USD | -1981.73% |
| 2014 Q1 | -802 Thousand USD | -231.26% |
| 2014 Q2 | -3.13 Million USD | -291.15% |
| 2014 Q3 | -3.21 Million USD | -2.49% |
| 2014 Q4 | -674 Thousand USD | 79.04% |
| 2013 Q3 | 1.23 Million USD | 171.86% |
| 2013 Q2 | -1.72 Million USD | -693.1% |
| 2013 Q1 | 290 Thousand USD | -35.84% |
| 2013 FY | 416 Thousand USD | 137.89% |
| 2013 Q4 | 611 Thousand USD | -50.57% |
| 2012 Q3 | 1.07 Million USD | 155.54% |
| 2012 Q1 | -690 Thousand USD | 62.4% |
| 2012 Q4 | 452 Thousand USD | -57.88% |
| 2012 Q2 | -1.93 Million USD | -180.0% |
| 2012 FY | -1.09 Million USD | 59.9% |
| 2011 Q3 | 1.1 Million USD | 212.51% |
| 2011 Q1 | -1.02 Million USD | 13.36% |
| 2011 Q2 | -983 Thousand USD | 4.1% |
| 2011 FY | -2.73 Million USD | 23.82% |
| 2011 Q4 | -1.83 Million USD | -265.91% |
| 2010 Q1 | -1.06 Million USD | -162.3% |
| 2010 Q3 | 935 Thousand USD | 141.04% |
| 2010 FY | -3.59 Million USD | 8.67% |
| 2010 Q4 | -1.18 Million USD | -226.52% |
| 2010 Q2 | -2.27 Million USD | -114.1% |
| 2009 Q2 | -4.62 Million USD | -109.45% |
| 2009 FY | -3.93 Million USD | 41.53% |
| 2009 Q1 | -2.21 Million USD | -10.53% |
| 2009 Q4 | 1.7 Million USD | 42.69% |
| 2009 Q3 | 1.19 Million USD | 125.86% |
| 2008 Q4 | -1.99 Million USD | -345.64% |
| 2008 Q3 | 814.04 Thousand USD | 127.47% |
| 2008 Q1 | -2.58 Million USD | -270.79% |
| 2008 Q2 | -2.96 Million USD | -14.79% |
| 2008 FY | -6.72 Million USD | -107.96% |
| 2007 Q3 | 1.15 Million USD | 130.35% |
| 2007 FY | -3.23 Million USD | -35.31% |
| 2007 Q1 | -2.08 Million USD | -297.28% |
| 2007 Q2 | -3.81 Million USD | -82.81% |
| 2007 Q4 | 1.51 Million USD | 30.46% |
| 2006 Q3 | 889.67 Thousand USD | 132.62% |
| 2006 FY | -2.39 Million USD | -180.27% |
| 2006 Q4 | 1.05 Million USD | 18.98% |
| 2006 Q2 | -2.72 Million USD | -69.12% |
| 2006 Q1 | -1.61 Million USD | -176.03% |
| 2005 Q1 | -194.93 Thousand USD | -109.89% |
| 2005 Q2 | -1.86 Million USD | -854.39% |
| 2005 FY | 2.97 Million USD | 1537.17% |
| 2005 Q3 | 2.91 Million USD | 256.62% |
| 2005 Q4 | 2.12 Million USD | -27.21% |
| 2004 Q3 | -56.39 Thousand USD | 93.82% |
| 2004 Q1 | -800.32 Thousand USD | -131.68% |
| 2004 Q2 | -912.47 Thousand USD | -14.01% |
| 2004 Q4 | 1.97 Million USD | 3596.8% |
| 2004 FY | 181.98 Thousand USD | -71.36% |
| 2003 Q4 | 2.52 Million USD | 2093.21% |
| 2003 Q2 | -1.08 Million USD | -17.57% |
| 2003 Q3 | 115.2 Thousand USD | 110.63% |
| 2003 FY | 635.53 Thousand USD | 112.03% |
| 2003 Q1 | -922.1 Thousand USD | 38.88% |
| 2002 Q2 | -1.48 Million USD | 14.77% |
| 2002 Q4 | -1.5 Million USD | -178.22% |
| 2002 Q3 | -542.25 Thousand USD | 63.55% |
| 2002 Q1 | -1.74 Million USD | -298.59% |
| 2002 FY | -5.28 Million USD | -1140.48% |
| 2001 Q3 | 121.59 Thousand USD | 113.95% |
| 2001 FY | -425.99 Thousand USD | 92.82% |
| 2001 Q1 | -555.2 Thousand USD | -1652.36% |
| 2001 Q2 | -871.38 Thousand USD | -56.95% |
| 2001 Q4 | 878.98 Thousand USD | 622.88% |
| 2000 Q4 | 35.76 Thousand USD | 157.61% |
| 2000 FY | -5.93 Million USD | 15.21% |
| 2000 Q3 | -62.08 Thousand USD | 96.57% |
| 2000 Q2 | -1.81 Million USD | 55.84% |
| 2000 Q1 | -4.09 Million USD | -173.24% |
| 1999 FY | -7 Million USD | -172.16% |
| 1999 Q1 | -3.5 Million USD | -189.74% |
| 1999 Q2 | -2 Million USD | 42.86% |
| 1999 Q3 | -200 Thousand USD | 90.0% |
| 1999 Q4 | -1.5 Million USD | -650.0% |
| 1998 Q4 | 3.9 Million USD | -13.33% |
| 1998 Q1 | 1.7 Million USD | -88.82% |
| 1998 Q3 | 4.5 Million USD | 1225.0% |
| 1998 FY | 9.7 Million USD | -72.52% |
| 1998 Q2 | -400 Thousand USD | -123.53% |
| 1997 Q1 | 10.9 Million USD | 467.71% |
| 1997 Q4 | 15.2 Million USD | 105.41% |
| 1997 Q2 | 1.7 Million USD | -84.4% |
| 1997 FY | 35.3 Million USD | 5142.86% |
| 1997 Q3 | 7.4 Million USD | 335.29% |
| 1996 FY | -700 Thousand USD | 0.0% |
| 1996 Q4 | 1.92 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 112.945% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -759.29% |
| Embecta Corp. | 221.5 Million USD | 109.758% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 124.651% |
| PainReform Ltd. | -9.58 Million USD | -125.511% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -351.654% |
| SCYNEXIS, Inc. | 72.66 Million USD | 129.742% |
| Journey Medical Corporation | -2.07 Million USD | -942.595% |
| Safety Shot Inc | -12.18 Million USD | -77.386% |
| Alpha Teknova, Inc. | -35.56 Million USD | 39.226% |
| Bright Green Corporation | -8.89 Million USD | -143.078% |
| Procaps Group, S.A. | 38.97 Million USD | 155.456% |
| Alvotech | -354.86 Million USD | 93.909% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 146.013% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -43.113% |
| Cosmos Health Inc. | -21.83 Million USD | 1.0% |
| Dynavax Technologies Corporation | -37.02 Million USD | 41.631% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 86.107% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 86.439% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -351.654% |
| Theratechnologies Inc. | -10.62 Million USD | -103.378% |
| Harrow Health, Inc. | 580 Thousand USD | 3826.379% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -359.753% |
| Biofrontera Inc. | -22.67 Million USD | 4.692% |
| DURECT Corporation | -36.88 Million USD | 41.403% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -310.192% |
| Cronos Group Inc. | -81.37 Million USD | 73.44% |
| OptiNose, Inc. | -22.74 Million USD | 4.989% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 110.339% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 44.799% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 271.097% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 272.559% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -398.418% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -247.99% |
| Radius Health, Inc. | -3.92 Million USD | -450.65% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -512.826% |
| Phibro Animal Health Corporation | 53.31 Million USD | 140.538% |
| Procaps Group S.A. | 52.32 Million USD | 141.306% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -153.584% |
| Viatris Inc. | 766.2 Million USD | 102.821% |
| Rockwell Medical, Inc. | -6.67 Million USD | -224.033% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -311.363% |
| SIGA Technologies, Inc. | 83.62 Million USD | 125.846% |
| Tilray Brands, Inc. | -174.74 Million USD | 87.632% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 331.626% |
| Shineco, Inc. | -17.06 Million USD | -26.645% |
| PetIQ, Inc. | 60.01 Million USD | 136.013% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -356.286% |
| Incannex Healthcare Limited | -30.04 Million USD | 28.055% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 108.614% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1369.273% |
| Silver Spike Investment Corp. | 7.34 Million USD | 394.451% |
| Assertio Holdings, Inc. | -243.53 Million USD | 91.125% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -266.796% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -58.716% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -38.598% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -7.795% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 84.321% |
| Hempacco Co., Inc. | -8.81 Million USD | -145.26% |
| Talphera, Inc. | -16.88 Million USD | -27.971% |
| Alvotech | -354.86 Million USD | 93.909% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 140.433% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 105.927% |
| Currenc Group, Inc. | -6.64 Million USD | -225.214% |
| Kamada Ltd. | 10.06 Million USD | 314.756% |
| Indivior PLC | -4 Million USD | -440.325% |
| Evoke Pharma, Inc. | -7.43 Million USD | -190.853% |
| Flora Growth Corp. | -50.35 Million USD | 57.078% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -7.795% |
| Evolus, Inc. | -49.23 Million USD | 56.101% |
| HUTCHMED (China) Limited | 18.37 Million USD | 217.622% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 110.972% |
| Akanda Corp. | -10.05 Million USD | -115.025% |